Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases
Augustine Therapeutics has raised $83.9M in total funding. The most recent round was Series A. The last funding was announced in March 2025.
Augustine Therapeutics's investors include Eli Lilly, Novo Holdings, Asabys Partners, AdBio partners, Jeito Capital.
Augustine Therapeutics is headquartered in Leuven, Belgium.
Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases
Augustine Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Augustine Therapeutics — Funding & Investors." VCBacked, March 24, 2025, https://www.vcbacked.co/company/augustine-therapeutics. Accessed July 25, 2026.
VCBacked. (2025). Augustine Therapeutics — Funding & Investors. Retrieved July 25, 2026, from https://www.vcbacked.co/company/augustine-therapeutics
{{cite web |title=Augustine Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/augustine-therapeutics |website=VCBacked |access-date=July 25, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated